OTCMKTS:UCBJF

UCB - UCBJF Stock Forecast, Price & News

$73.25

0.00 (0.00%)

(As of 09/23/2022 12:00 AM ET)

Add

Compare

Today's Range: $73.25
▼
$73.25
50-Day Range: $68.96
▼
$85.60
52-Week Range: $68.96
▼
$122.90

Volume: N/A
Average Volume: 479 shs
Market Capitalization: $13.85 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $101.71

UCB MarketRank™ Forecast

Analyst Rating: Hold
2.11 Rating Score
Upside/Downside: 38.9% Upside
$101.71 Price Target
Short Interest: Healthy
0.29% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.99
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 28.99%
From $4.14 to $5.34 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

4.1

Analyst's Opinion

Consensus Rating
UCB has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 3 buy ratings, 5 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $101.71, UCB has a forecasted upside of 38.9% from its current price of $73.25.
Amount of Analyst Coverage
UCB has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
0.29% of the outstanding shares of UCB have been sold short.
Short Interest Ratio / Days to Cover
UCB has a short interest ratio ("days to cover") of 1839.7, which indicates bearish sentiment.
Change versus previous month
Short interest in UCB has recently decreased by 17.48%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
UCB does not currently pay a dividend.
Dividend Growth
UCB does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for UCBJF.

2.8

News and Social Media Coverage

News Sentiment
UCB has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for UCB this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added UCB to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

N/A

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, UCB insiders have not sold or bought any company stock.

1.9

Earnings and Valuation

Earnings Growth
Earnings for UCB are expected to grow by 28.99% in the coming year, from $4.14 to $5.34 per share.
Price to Book Value per Share Ratio
UCB has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About UCB (OTCMKTS:UCBJF) Stock

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Receive UCBJF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

UCBJF Stock News Headlines

September 24, 2022 | americanbankingnews.com

UCB (OTCMKTS:UCBJF) Upgraded by Jefferies Financial Group to "Buy"

September 18, 2022 | americanbankingnews.com

Short Interest in UCB SA (OTCMKTS:UCBJF) Drops By 17.5%

September 16, 2022 | americanbankingnews.com

UCB (OTCMKTS:UCBJF) Lifted to "Neutral" at Citigroup

September 15, 2022 | americanbankingnews.com

UCB (OTCMKTS:UCBJF) Lowered to "Underperform" at Credit Suisse Group

September 14, 2022 | americanbankingnews.com

UCB (OTCMKTS:UCBJF) Sets New 52-Week Low at $68.96

April 25, 2022 | finance.yahoo.com

Here's Why Momentum in UCB SA (UCBJF) Should Keep going

March 31, 2022 | msn.com

What Makes UCB SA (UCBJF) a Good Fit for "Trend Investing"

March 25, 2022 | finanznachrichten.de

UCB SA/NV - CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS 2022

February 7, 2022 | seekingalpha.com

Biogen signs licensing deal with Xbrane for potential biosimilar to Cimzia

January 23, 2022 | finance.yahoo.com

ZGNX Jan 2022 7.000 call

January 21, 2022 | msn.com

Why Zogenix Flew Higher Before Leveling Off This Week

January 19, 2022 | markets.businessinsider.com

UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights

November 5, 2021 | finance.yahoo.com

UCB Showcases Key Rheumatology Data at ACR Convergence 2021

October 20, 2021 | finance.yahoo.com

UCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Lab

October 16, 2021 | msn.com

BRIEF-UCB SA Gives An Update On U.S. FDA Review Of Biologics License Application (BLA) For Bimekizumab

September 29, 2021 | finance.yahoo.com

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

August 27, 2021 | benzinga.com

Why New Oriental Education Shares Are Falling

August 12, 2021 | finance.yahoo.com

SpectrumDNA, Inc. (SPXA)

March 26, 2021 | finance.yahoo.com

UCB SA/NV - Convening notice annual shareholders meeting

February 28, 2021 | seekingalpha.com

UCB SA (UCBJF) CEO Jean-Christophe Tellier on Q4 2020 Results - Earnings Call Transcript

February 23, 2021 | finance.yahoo.com

UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

January 13, 2021 | finance.yahoo.com

UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy

December 1, 2020 | finance.yahoo.com

Specifica Delivers Antibody Platform to UCB to Speed up Development of New Therapeutics

November 30, 2020 | finance.yahoo.com

World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19

November 18, 2020 | finance.yahoo.com

UCB unleashes the power of data in new collaboration

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive UCBJF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

UCBJF Company Calendar

Today: 9/24/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:UCBJF
CUSIP: N/A
CIK: 1290640
Web: www.ucb.com
Phone: (322) 559-9999
Fax: 32-2559-9900
Employees: 8,561
Year Founded: 1928

Price Target and Rating

Average Stock Price Forecast: $101.71
High Stock Price Forecast: $120.00
Low Stock Price Forecast: $86.00
Forecasted Upside/Downside: +38.9%
Consensus Rating: Hold
Rating Score (0-4): 2.11
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.25
Current Ratio: 1.31
Quick Ratio: 1.00

Sales & Book Value

Annual Sales: $6.84 billion
Price / Sales: 2.03
Cash Flow: $7.67 per share
Price / Cash Flow: 9.55
Book Value: $52.49 per share
Price / Book: 1.40

Miscellaneous

Outstanding Shares: 189,020,000
Free Float: N/A
Market Cap: $13.85 billion
Optionable: Not Optionable
Beta: 0.63

Social Links

Key Executives

Mr. Jean-Christophe Tellier (Age 63)
CEO & Exec. Director
Comp: $4.37M

Ms. Sandrine Dufour CFA (Age 56)
Exec. VP & CFO

Ms. Kirsten Lund-Jurgensen (Age 63)
Exec. VP of Supply & Technology Solutions

Dr. Dhavalkumar D. Patel M.D. (Age 61)
Ph.D., Exec. VP & Chief Scientific Officer

Mr. William J. Silbey (Age 63)
Exec. VP & Gen. Counsel

Mr. Jean-Luc Fleurial (Age 57)
Exec. VP & Chief HR Officer

Prof. Iris Low-Friedrich (Age 62)
Exec. VP, Chief Medical Officer and Head of Devel. & Medical Patient Value Practices

Mr. Emmanuel Caeymaex (Age 53)
Exec. VP of Immunology Solutions & Head of US

Mr. Charl van Zyl (Age 55)
Exec. VP of Neurology Solutions & Head of EU/International

Ms. Caroline Vancoillie
Chief Accounting Officer & CFO of Patient Value Functions

Key Competitors

View All Competitors

UCBJF Stock - Frequently Asked Questions

Should I buy or sell UCB stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" UCBJF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in UCBJF, but not buy additional shares or sell existing shares.
View UCBJF analyst ratings or view top-rated stocks.
What is UCB's stock price forecast for 2022?: 9 equities research analysts have issued 1 year target prices for UCB's stock. Their UCBJF share price forecasts range from $86.00 to $120.00. On average, they predict the company's stock price to reach $101.71 in the next year. This suggests a possible upside of 38.9% from the stock's current price.
View analysts price targets for UCBJF or view top-rated stocks among Wall Street analysts.
How have UCBJF shares performed in 2022?: UCB's stock was trading at $107.96 on January 1st, 2022. Since then, UCBJF shares have decreased by 32.2% and is now trading at $73.25.
View the best growth stocks for 2022 here.
Are investors shorting UCB?: UCB saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 551,900 shares, a decline of 17.5% from the August 15th total of 668,800 shares. Based on an average daily volume of 300 shares, the days-to-cover ratio is presently 1,839.7 days.
View UCB's Short Interest.

What is UCB's stock symbol?: UCB trades on the OTCMKTS under the ticker symbol "UCBJF."
How do I buy shares of UCB?: Shares of UCBJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is UCB's stock price today?: One share of UCBJF stock can currently be purchased for approximately $73.25.
How much money does UCB make?: UCB (OTCMKTS:UCBJF) has a market capitalization of $13.85 billion and generates $6.84 billion in revenue each year.
How many employees does UCB have?: The company employs 8,561 workers across the globe.
How can I contact UCB?: UCB's mailing address is Allee de la Recherche 60, Brussels C9, 1070. The official website for the company is www.ucb.com. The company can be reached via phone at (322) 559-9999, via email at investor-relations@ucb.com, or via fax at 32-2559-9900.

This page (OTCMKTS:UCBJF) was last updated on 9/24/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial Subscription Here

UCB - UCBJF Stock Forecast, Price & News

UCB MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month